Eiji Kumazawa

765 citations
25 papers · 634 indexed · h-index 16
Topics
Cancer therapeutics and mechanisms (12 papers)Synthesis and biological activity (5 papers)Cancer, Lipids, and Metabolism (4 papers)
Partner nations
JapanGermany

In The Last Decade

Eiji Kumazawa

25 papers receiving 599 citations

Peers

Eiji Kumazawa
Comparison fields: 5 of 68
  • Molecular Biology 388
  • Oncology 290
  • Organic Chemistry 131
  • Immunology 64
  • Pharmacology 57
Replace Akinobu Kurita with:
Akinobu Kurita Japan
M K Ritke United States
Y.-H. Ling United States
Tohru Obata Japan
Hennie M.M. Schlüper Netherlands
S. CROS France
Elisabetta Corna Italy
Sabina Y. van der Zanden Netherlands
Seojeong Park South Korea
H. H. Fiebig Germany
Eiji Kumazawa relative to Akinobu Kurita Japan Akinobu Kurita's profile →
Citations per field
00.5×1.6×
Akinobu Kurita · 1×
Citations per year

Countries citing papers authored by Eiji Kumazawa

Since Specialization
Citations

This map shows the geographic impact of Eiji Kumazawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eiji Kumazawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eiji Kumazawa more than expected).

Fields of papers citing papers by Eiji Kumazawa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eiji Kumazawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eiji Kumazawa. The network helps show where Eiji Kumazawa may publish in the future.

Co-authorship network of co-authors of Eiji Kumazawa

This figure shows the co-authorship network connecting the top 25 collaborators of Eiji Kumazawa. A scholar is included among the top collaborators of Eiji Kumazawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eiji Kumazawa. Eiji Kumazawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 4
2 22
3 26
4 14
5
Antitumor activity of new combination chemotherapy with irinotecan hydrochloride and nedaplatin against human cervical cancer cell lines.
3
6 15
7 18
8 24
9 22
10 68
11 6
12 34
13 21
14 134
15 9
16
DT-5461a, an antitumor synthetic lipid a analog, causes selective blood flow reduction in tumor tissue.
10
17 12
18 18
19 15
20 28

About Eiji Kumazawa

Eiji Kumazawa is a scholar working on Toxicology, Cancer Research and Oncology, having authored 25 papers that have together received 634 indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (12 papers), Synthesis and biological activity (5 papers) and Cancer, Lipids, and Metabolism (4 papers). The work is most often cited by research in Toxicology (44 citations), Oncology (290 citations) and Molecular Biology (388 citations). Eiji Kumazawa has collaborated with scholars based in Japan and Germany. Frequent co-authors include Akiko Tohgo, Yusuke Ochi, Akio Ejima, Takeshi Jimbo, Masamichi Sugimori, Satoru Ohsuki, Ikuo Mitsui, Kouichi Uoto, Hirofumi Terasawa and Masashi Aonuma. Their work appears in journals such as Blood, Pharmaceutical Research and Advances in experimental medicine and biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026